DNA Damage Sensing and TP53 Function as Modulators of Sensitivity to Calicheamicin-Based Antibody–Drug Conjugates for Acute Leukemia
These results support further evaluation of combination therapies with corresponding small-molecule inhibitors (currently pursued for therapy of other cancers) toward clinical testing as novel strategies to increase the efficacy of CLM-based ADCs such as GO and InO.
Authors
- Roland B. Walter (ORCID: https://orcid.org/0000-0002-9268-3341)
- Allie R. Kehret (ORCID: https://orcid.org/0000-0002-3186-566X)
- Frances M. Cole
- Pritha Chanana (ORCID: https://orcid.org/0000-0003-2255-8905)
- James C. Barton (ORCID: https://orcid.org/0000-0003-2876-8276)
- Margery Gang (ORCID: https://orcid.org/0000-0001-8480-6260)
- Colin D. Godwin (ORCID: https://orcid.org/0000-0002-6564-9690)
- J. Li
- Sarah Erraiss
- Eduardo P Rodríguez-Arbolí
- George S. Laszlo (ORCID: https://orcid.org/0000-0001-8580-2659)
- Camryn Pettenger-Willey
- Meghann M. Yochim
Institutions
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- Instituto de Biomedicina de Sevilla (ES)
Publication Details
- Journal
- Cancers
- Published
- 2025-12-25
- DOI
- https://doi.org/10.3390/cancers18010067
- Primary Topic
- Cancer therapeutics and mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00